drugset / Trial / NCT00000401
Oral Collagen for Rheumatoid Arthritis
Phase 2
Completed
110 enrolled
University of Tennessee
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
Timeline
- Start
- 1999-07
- Primary completion
- 2005-08
- Completion
- 2005-08
Publications
- Background Postlethwaite AE. Can we induce tolerance in rheumatoid arthritis? Curr Rheumatol Rep. 2001 Feb;3(1):64-9. doi: 10.1007/s11926-001-0052-z.
- Results Carbone LD, McKown K, Pugazhenthi M, Barrow KD, Warrington K, Somes G, Postlethwaite AE. Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum. 2004 Aug;50(8):2713-5. doi: 10.1002/art.20361. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bovine type II collagen | Protein / enzyme biologic | 70 ug | Oral |
| Subject | bovine type II collagen | Protein / enzyme biologic | 130 ug | Oral |